Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial

Thorsten M. Leucker, Michael J. Blaha, Steven R. Jones, Michael A. Vavuranakis, Marlene S. Williams, Hong Lai, Thomas Schindler, Jacqueline Latina, Steven P. Schulman, Gary Gerstenblith

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)419-421
Number of pages3
Issue number4
StatePublished - Jul 28 2020


  • acute coronary syndrome
  • cholesterol, LDL
  • evolocumab
  • secondary prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this